

Amino acid derivatives. Part 6. New analogs of the angiotensin-converting enzyme 'Captopril'. Synthesis and anti-HIV activity

Najim A. Al-Masoudi,^{a*} Nawar S. Hamad,^a Shahid Hameed,^b
and Christophe Pannecouque^c

^aChemistry Department, College of Science, University of Basrah, Basrah, Iraq

^bDepartment of Chemistry, Quaid-I-Azam University, Islamabad-45320, Pakistan

^cRega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium

E-mail: najim.al-masoudi@gmx.de

DOI: <http://dx.doi.org/10.3998/ark.5550190.0011.b20>

Abstract

The development of new HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs) offers the possibility of generating structures of increased potency. On this basis, new derivatives of the angiotensin-converting enzyme 'Captopril' bearing benzimidazoles, benzothiazole, purine and pyridine residues were synthesized with the aim of developing new NNRTIs. Alternatively, the thioether analogs bearing carboxymethylthio, 2-amino-2-oxo-ethylthio, 2-(phthalimido-2-yl)-2-ethylthio, 1-benzyl-2-ethyl-4-nitro-imidazol-5-yl)-piperazin-1-yl)-2-oxo-ethylthio, and the carboxamide analogs were prepared from condensation of Captopril with various halide derivatives. The new compounds were assayed against HIV-1 and HIV-2 in MT-4 cells. The compound having a 4-chlorobenzimidazole group was the most active in inhibiting HIV-1, with $EC_{50} = 0.24 \mu\text{g/ml}$, with therapeutic indexes (SI) of 21, is a leading candidate for further development.


Keywords: Anti-HIV activity, benzimidazole, Captopril, non-nucleoside reverse transcriptase inhibitors (NNRTIs)

Introduction

The global spread and fatal prognosis of human immunodeficiency virus (HIV) infection emphasize the urgent need for effective antiretroviral therapies. The introduction of highly active antiretroviral therapy (HAART) based on a combination of HIV-1 reverse transcriptase (RT) and protease inhibitors to treat AIDS has had a dramatic impact on the morbidity and mortality of individuals infected by the HIV.¹⁻⁵ Kaletra, the first second-generation protease inhibitor to reach drug status, is a mixture of two protease inhibitors, lopinavir^{6,7} and ritonavir.⁸ Lopinavir, which constitutes a peptide backbone, was originally designed to diminish the interactions of inhibitor

with Val82 HIV-1 PR, a residue that is often mutated in the drug-resistant strains of the virus.³ On the other hand, benzimidazoles are very useful intermediates/subunits for the development of molecules of pharmaceutical or biological interest including anti-ulcers, antihypertensive antivirals, antifungals, anticancer compounds, and antihistaminics.⁹ Moreover, some benzimidazoles have been reported as new HIV-1 reverse transcriptase inhibitors, and/or potent DNA gyrase inhibitors.⁹ In recent years, many research groups have been engaged in the development of new non-nucleoside RT inhibitors (NNRTI) having benzimidazole backbone such as thiazolo[3,4-*a*]benzimidazoles (TBZs) and their analogs as potent anti-HIV agents¹⁰⁻¹³ and 1-(2,6-difluorophenyl)-thiazolo[3,4-*a*]benzimidazole **1** (NSC625487) is a one example of TBZs with a highly potential inhibitory of HIV-1-induced cytopathic effect in a variety of human cell lines, meanwhile it inhibited the replication of various strains of HIV-1 including a zidovudine resistant strain (G910-6)¹³. Monforte *et al.*¹⁴ have reported the synthesis of new thiazolo[3,4-*a*]benzimidazoles and 2-aryl-1-benzylbenzimidazoles as HIV-1 RT inhibitors.

In continuation for our attempts in searching for new anti-HIV agents,¹⁵⁻²³ and on the basis of above promising biological results, we considered benzimidazoles and their analogs particularly interesting to optimize the synthetic approaches to our antiviral agents. In this study, the angiotensin-converting enzyme (ACE) inhibitor 'captopril'²⁴ has been selected as a main backbone for the synthesis of new benzimidazole, benzothiazole derivatives and their analogs as well as the thioether-captopril analogs, utilizing microwave irradiation method.




Results and Discussion

Treatment of Captopril **2** with the appropriate 1,2-aryldiamine in the presence of *p*-toluenesulfonic acid (*p*-TsOH) and Al₂O₃ under irradiation in MW (10 min, 100-150 W) afforded the benzimidazole bearing captopril **2** and the related analogs **9-14**, isolated by conventional work-up, in 51-72% yield. The structures of **9-14** were assigned on the basis of their ¹H-, and ¹³C- NMR and mass spectra, since they showed similar patterns of aliphatic H-atoms. Compounds **9-11** and **14** showed multiplets or doublets at higher field (δ 8.67-7.21), attributed to the aryl groups. C-6 and C-4 of pyridine residue at **12** appeared as doublet of doublets at δ 8.67 and 7.81 ($J = 7.9$ Hz, 3.1 Hz), while C-5 resonated as triplet at δ 7.43 ($J = 7.9$ Hz). C-4 and C-5 of the purine moiety at **13** appeared as singlets at δ 8.89 and 8.83, respectively. Compounds **9-14** demonstrated doublet of doublets at the region δ 4.60-4.71, assigned to H-2 of

pyrrolidine ring ($J_{2,3a} \sim 3.6$ Hz, $J_{2,3b} \sim 8.0$ Hz, $J_{3a,3b} \sim 11.5$ Hz), while the multiplets at the regions δ 3.60-3.64, δ 2.11-2.45 and δ 1.97-2.11 were assigned to C-5, C-3 and C-4 of the pyrrolidine ring, respectively. The H-2' and CH₂SH signals appeared as multiplets in the region δ 2.98-3.11. The doublets at δ 1.23-1.29 were attributed to methyl group at C-2' ($J \sim 3.0$ Hz, CH₃). The ¹³C-NMR spectra of **9-12** were characterized (Experimental Section), since compound **13** was selected for the ¹³C-NMR analysis. The spectrum demonstrated a higher field signal at δ 177.1 that was assigned to C=O, since the resonance at δ 152.5 was attributed to C-6 and C-7a of the benzimidazole ring. C-2 and C-4 of the same ring appeared at δ 147.8. The signal at δ 132.3 was assigned to C-3a of the benzimidazole. The pyrrolidine carbon atoms C-2, C-5, C-3 and C-4 were at δ 59.9, 47.5, 38.2 and 21.3, respectively. The HSCH₂CH- appeared at δ 41.5, while HSCH₂CH resonated at δ 24.1 (HSCH₂CH). The resonance at δ 16.9 was attributed to the methyl group.

The purine derivative **13** was selected for further spectroscopic analysis. From the gradient selected HMBC spectrum²⁵ of **13**, H-2' at δ_H 3.05 showed two heteronuclear ²J_{C,H} correlations: one with C=O at δ_C 177.1 and the other with HSCH₂ at δ_C 24.1. Further, H-2 of the pyrrolidine ring at δ_H 4.68 exhibited two ²J_{C,H} correlations: one with C-2 of the benzimidazole residue at δ_C 147.8 and the other with C-3 of the pyrrolidine ring at δ_C 38.2. A ³J_{C,H} correlation observed between H-2 and C-5 of the pyrrolidine at δ_C 47.5 ppm. H-4 of the purine ring at δ_H 6.89 showed a ²J_{C,H} correlation with C-6 of the same ring at δ_C 152.5.




Scheme 1. Synthesis of benzimidazoles **9-11**, imidazolo-pyridine **12**, purine **13** and benzothiazole **14** derivatives from Captopril **2** and various aryl diamines **3-7**.

Next, other models of captopril derivatives bearing a thioether linkage were prepared, aiming to evaluate their anti-HIV activity. Roark *et al.*²⁶ have prepared *S*-1-[2-(1-carboxy-3-phenyl-

propylsulphanyl)-propionyl]-pyrrolidine-2-carboxylic acid, as a potential thioether-captopril derivative. Treatment of **2** with chloro compounds: 2-chloroacetic acid, 2-chloroacetamide, 2-chloroethyl-phthalimide or 1-(4-(1-benzyl-2-ethyl-4-nitro-imidazol-5-yl)piperazin-1-yl)-2-chloroethanone **18**²⁷ in the presence of Et₃N or NH₄OAc afforded **15-17** and **19** in 68, 72, 78 and 67% yield, respectively.


The assignment of protons and carbons of the captopril backbone was deduced in comparison to compounds **9-14**. Compounds **15**, **16** and **19** showed singlets at δ 3.66, 3.59 and 3.61, assigned to the methylene protons of the SCH₂CO group, while **17** showed a multiplet in the region δ 2.85-2.79, attributed to the protons of SCH₂CHMe + SCH₂CH₂-phthalimido groups. In the ¹³C-NMR spectra of **15-17** and **19**, C=O resonated at the higher field (δ 179.9-173.4). The resonances at δ 42.1, 43.7, 28.6 and 40.0 were attributed to (DCO₂CH₂S), (D₂NCOCH₂S), (SCH₂CH₂-phthalimide + C³_{pyrrol.}) and (SCH₂CHMe + SCH₂CO) carbon atoms of **15-17** and **19**, respectively. The aromatic and piperazine carbon atoms have been analyzed. Compound **16** was selected for further NMR spectroscopic study. From the gradient selected HMBC spectrum of **16**, the methylene protons of CH₂COND₂ (δ _H 3.59) showed a ^{1,2}J_{C,H} correlations with the carbon of the COND₂ at δ _C 169.4, in addition to a ^{1,3}J_{C,H} correlation with the carbon of the methylene group of the MeCHCH₂S group at δ _C 34.3. A ^{1,2}J_{C,H} correlation appeared between the proton of the MeCHCH₂S group (δ _H 2.80) and the carbon atom of the C=O group (C-2) at δ _C 177.9.



Scheme 2. Reagents and conditions. (i) 2-chloroacetic acid, Et₃N, DMF, 23 °C, 16 h; (ii) 2-chloroacetamide; Et₃N, DMF, 23 °C, 16 h; (iii) 2-chloroethylphthalimide, Et₃N, EtOH, reflux, 5 h; (iv) **18**, EtOH, NaOAc, 23 °C, 16 h.

A suitable coupling method²⁷ was employed for the formation of peptides by reaction of the carboxylic acid group with acylated amino acid, using 1-hydroxybenzotriazole (HOBt)^{28,29} and *N,N'*-dicyclohexylcarbodiimide (DCC)³⁰ as coupling reagents. HOBt **1** is currently the most frequently used activating agent for the carboxyl group of amino acids. The procedure is fast and suppresses racemization, especially in the presence of DCC.³¹

Amide **21** was prepared (70% yield) by coupling **20** with Captopril **2**³² (L-proline derivative) in the presence of HOBt and DCC as coupling reagents (Scheme 3). The structure of **21** was determined by the ¹H-, ¹³C- NMR and mass spectra. The L-proline protons showed a similar pattern for those of **15-17**. The CH₂ of the amide group appeared as singlet at δ□ 3.97, while the broad singlet at δ□ 3.42 was assigned to the piperazine protons. The four aromatic protons were appeared as multiplet at the region δ 8.21-7.49. The ¹³C- NMR spectrum of **21** contained similar resonance signals of the l-proline carbons ring C-2 - C-5. The chemical shifts between δ 177.9 and 167.7 were assigned to the carbonyl groups, while the resonance at δ 166.6 and 147.8 were assigned to C-2 and C-3a of the benzothiazole ring, respectively. The resonances at δ 49.3 and 46.5 were attributed to the piperazine carbons. The carbons of CH₂NCO and CHCH₂SH groups were oriented at δ 40.9 ppm, while the carbon of CHCH₂SH group appeared at δ 24.2 ppm. The mass fragmentation pattern was consistent with the suggested structure, however, the FABMAS spectrum showed a protonated molecular ion at *m/z* 476 [M+H]⁺.



Scheme 3. Synthesis of the amide derivative **21** from Captopril **2** and the benzothiazole derivative **20**.

In vitro anti-HIV assay

Compounds **9-17**, **19** and **21** were tested for their *in vitro* anti-HIV-1 (strain III_B) and HIV-2 (strain ROD) activity in human T-lymphocyte (MT-4) cells. based on MTT assay.³³ The results are summarized in Table 1, in which the data for Nevirapine (BOE/BIRG587)³⁴ and

azidothymidine (DDN/AZT).³⁵ were included for comparison purposes. Compound **11** was found to be the only compound in the series inhibiting HIV-1 replication in cell culture with EC₅₀ of 0.24 µg/mL and a CC₅₀ of 5.12 µg/mL, resulting in a selectivity index of 21.

Table 1. *In vitro* anti-HIV-1^a and HIV^b activity of compounds **9-17** and **19-21**

| Entry | Virus strain | EC ₅₀ (µg/ml) ^c | CC ₅₀ (µg/ml) ^d | SI ^e | Entry | Virus strain | EC ₅₀ (µg/ml) ^c | CC ₅₀ (µg/ml) ^d | SI ^e |
|------------|------------------|---------------------------------------|---------------------------------------|-----------------|-----------|------------------|---------------------------------------|---------------------------------------|-----------------|
| 9 | III _B | >11.27 | 11.27 | <1 | 10 | III _B | >28.17 | 28.17 | <1 |
| | ROD | >11.27 | 11.27 | <1 | | ROD | >28.17 | 28.17 | <1 |
| 11 | III _B | 0.24 | 5.12 | 21 | 12 | III _B | >59.05 | 59.05 | <1 |
| | ROD | >4.24 | 4.24 | <1 | | ROD | >59.05 | 59.05 | <1 |
| 13 | III _B | >24.70 | 24.70 | <1 | 14 | III _B | >15.80 | 15.80 | <1 |
| | ROD | >24.70 | 24.70 | <1 | | ROD | >15.80 | 15.80 | <1 |
| 15 | III _B | >125.00 | 125.00 | <1 | 16 | III _B | >3.12 | 3.12 | <1 |
| | ROD | >125.00 | 125.00 | <1 | | ROD | >3.12 | 3.12 | <1 |
| 17 | III _B | >22.43 | 22.43 | <1 | 19 | III _B | >2.23 | 2.23 | <1 |
| | ROD | >22.43 | 22.43 | <1 | | ROD | >2.23 | 2.23 | <1 |
| Nevirapine | III _B | 0.05 | >4.00 | >80 | 21 | III _B | >1.21 | 1.21 | <1 |
| | ROD | >4.00 | >4.00 | <1 | | ROD | >1.21 | 1.21 | <1 |
| AZT | III _B | 0.0022 | >25.00 | >11587 | | | | | |
| | ROD | 0.00094 | >25.00 | >26731 | | | | | |

^aAnti-HIV-1 activity measured with strain III_B. ^bAnti-HIV-2 activity measured with strain ROD. ^cCompound concentration required to achieve 50% protection of MT-4 cells from the HIV-1- and 2-induced cytopathogenic effect. ^dCompound concentration that reduces the viability of mock-infected MT-4 cells by 50%. ^eSI: Selectivity index (CC₅₀/EC₅₀).

Experimental Section

General. Melting points were measured on a Büchi melting point apparatus B-545 (BÜCHI Labortechnik AG, Switzerland) and are uncorrected. Microanalytical data were obtained with a Vario, Elementar apparatus (Shimadzu, Japan). NMR spectra were recorded on 300 and 600 MHz (¹H) and at 150.91 MHz (¹³C) spectrometers (Bruker, Germany) with TMS as internal standard and on δ scale in ppm. Heteronuclear assignments were verified by ¹H-¹³C HMBC experiment. Mass spectra were recorded on 70 eV EI and FAB MAT 8200 spectrometers (Finnegan MAT, USA), using 3-nitrobenzyl alcohol (NBOH) or glycerol as matrixes. Some molecular ions were detected by doping the sample with Na⁺ ion. Microwave-assisted reactions were carried out in a CEM Focused Microwave Synthesis System (100-150W).

General procedure for preparation of captopril bearing benzimidazole and benzothiazole derivatives (9-14)

A mixture of captopril **2** in (326 mg, 1.5 mmol), 1,2-aryldiamine (1.0 mmol), *p*-toluenesulfonic acid (*p*-TsOH) (10 mg) and Al₂O₃ (20 mg) is thoroughly ground with a pestle in a mortar at room temperature in an open atmosphere then irradiated in MW. After the reaction is completed, the mixture is allowed to cool to room temperature and then partitioned between CHCl₃ (3x15 ml) and dil. solution of NaHCO₃ (15 ml). The combined organic extracts was dried (Na₂SO₄), filtered and evaporated to dryness. The crude product was purified on a column of SiO₂ (5 g) by elution, in gradient, with MeOH (0-10%) and CHCl₃ as eluent to give the desired product.

1-(2-(Benzimidazol-2-yl)pyrrolidine-1-yl)-3-mercapto-2-methylpropan-1-one (9). From the *o*-phenylenediamine **3** (108 mg). Yield: 188 mg, (65%), mp 136-140 °C. ¹H NMR (CDCl₃): δ_H 7.85 (d, 2H, *J* = 8.0 Hz, Ar-H); 7.21 (d, 2H, *J* = 8.0 Hz, Ar-H); 4.60 (dd, 1H, *J*_{2,3a} = 3.7 Hz, *J*_{2,3b} = 8.0 Hz, *J*_{3a,3b} = 11.4 Hz, H-2); 3.64 (m, 2H, CH₂^{pyrrol.}-5); 3.04 (m, 3H, HSCH₂ + H-2'); 2.41 (m, 2H, CH₂^{pyrrol.}-3); 2.04 (m, 2H, CH₂^{pyrrol.}-4); 1.28 (d, 3H, *J* = 3.0 Hz, CH₃). ¹³C-NMR (CDCl₃): δ_C 176.7 (C=O); 140.8 (C²_{benzimid.}); 130.1 (C^{3a}_{benzimid.} + C^{7a}_{benzimid.}); 124.4 (C⁵_{benzimid.} + C⁶_{benzimid.}); 115.1 (C⁴_{benzimid.} + C⁷_{benzimid.}); 60.0 (C²_{pyrrol.}); 47.9 (C⁵_{pyrro}); 42.0 (HSCH₂CH); 38.1 (C³_{pyrrol.}); 24.8; (HSCH₂CH); 21.4 (C⁴_{pyrrol.}); 17.2 (CH₃). Anal. Calc. for C₁₅H₁₉N₃OS (289.4): C, 62.25; H, 6.62; N, 14.52%. Found: C, 61.97; H, 6.51; N, 14.32%. MS: *m/z* (FAB) 290 [M+H]⁺.

3-Mercapto-2-methyl-1-(2-(4-nitro-1H-benzimidazol-2-yl)pyrrolidin-1-yl)propan-1-one(10). From 3-nitrobenzene-1,2-diamine **4** (153 mg). Yield: 194 mg (58%), oil. ¹H NMR (CDCl₃): δ_H 8.16-7.43 (m, 3H, Ar-H); 4.63 (dd, 1H, *J*_{2,3a} = 3.5 Hz, *J*_{2,3b} = 8.1 Hz, *J*_{3a,3b} = 11.5 Hz, H-2); 3.62 (m, 2H, CH₂^{pyrrol.}-5); 3.10 (m, 3H, HSCH₂ + H-2'); 2.43 (m, 2H, CH₂^{pyrrol.}-3); 2.11 (m, 2H, CH₂^{pyrrol.}-4); 1.25 (d, 3H, *J* = 3.2 Hz, CH₃). ¹³C NMR (CDCl₃): δ_C 177.1 (C=O); 141.1 (C²_{benzimid.}); 138.8 (C^{7a}_{benzimid.}); 134.8 (C⁴_{benzimid.}); 131.8 (C^{3a}_{benzimid.}); + 124.0 (C⁶_{benzimid.}); 120.5 (C⁷_{benzimid.}); + 117.7 (C⁵_{benzimid.}); 58.3 (C²_{pyrrol.}); 47.5 (C⁵_{pyrro}); 42.2 (HSCH₂CH); 38.3 (C³_{pyrrol.}); 24.2; (HSCH₂CH); 22.6 (C⁴_{pyrrol.}); 17.0 (CH₃). MS: *m/z* (FAB) 335 [M+H]⁺; 357 [M+Na]⁺.

1-(2-(4-Chloro-1H-benzimidazol-2-yl)pyrrolidin-1-yl)-3-mercapto-2-methylpropan-1-one (11). From 3-chlorobenzene-1,2-diamine **5** (142 mg). Yield: 233 mg (72%), mp 122-125 °C. ¹H NMR (CDCl₃): δ_H 7.55-7.21 (m, 3H, Ar-H); 4.71 (dd, 1H, *J*_{2,3a} = 3.6 Hz, *J*_{2,3b} = 7.8 Hz, *J*_{3a,3b} = 11.4 Hz, H-2); 3.60 (m, 2H, CH₂^{pyrrol.}-5); 2.98 (m, 3H, HSCH₂ + H-2'); 2.40 (m, 2H, CH₂^{pyrrol.}-3); 2.00 (m, 2H, CH₂^{pyrrol.}-4); 1.25 (d, 3H, *J* = 3.0 Hz, CH₃). ¹³C NMR (CDCl₃): δ_C 177.4 (C=O); 141.0 (C²_{benzimid.}); 137.8 (C^{3a}_{benzimid.} + C^{7a}_{benzimid.}); 124.2 (C⁵_{benzimid.} + C⁶_{benzimid.}); 119.7 (C⁷_{benzimid.}); 113.0 (C⁷_{benzimid.}); 59.3 (C²_{pyrrol.}); 47.2 (C⁵_{pyrro}); 41.6 (HSCH₂CH); 38.0 (C³_{pyrrol.}); 24.5; (HSCH₂CH); 21.1 (C⁴_{pyrrol.}); 17.0 (CH₃). Anal. Calc. for C₁₅H₁₉N₃OS (289.4): C, 62.25; H, 6.62; N, 14.52. Found: C, 61.97; H, 6.51; N, 14.32. MS: *m/z* (FAB) 290 [M+H]⁺. Anal. Calc. for C₁₅H₁₈ClN₃OS (323.84): C, 55.63; H, 5.60; N, 12.98. Found: C, 55.41; H, 5.51; N, 12.72%. MS: *m/z* (FAB) 322/324 [M+H]⁺.

1-(2-(3H-Imidazol-[4,5-*b*]pyridine-2-yl)pyrrolidin-1-yl)-3-mercapto-2-methylpropan-1-one (12). From pyridine-2,3-diamine **6** (109 mg). Yield: 171 mg (59%), semi-solid. ¹H NMR (CDCl₃): δ_H 8.67 (dd, 1H, *J* = 7.8 Hz, 3.0 Hz, C⁶_{pyrid.}); 7.82 (dd, 1H *J* = 7.9 Hz, 3.1 Hz, C⁴_{pyrid.}); 7.43 (t, 1H *J*

= 7.9 Hz, C⁵_{pyrid.}); 4.71 (dd, 1H, $J_{2,3a} = 3.8$ Hz, $J_{2,3b} = 8.2$ Hz, $J_{3a,3b} = 11.6$ Hz, H-2); 3.63 (m, 2H, CH₂^{pyrrol.-5}); 3.11 (m, 3H, HSCH₂ + H-2'); 2.45 (m, 2H, CH₂^{pyrrol.-3}); 2.03 (m, 2H, CH₂^{pyrrol.-4}); 1.25 (d, 3H, $J = 3.0$ Hz, CH₃). ¹³C NMR (CDCl₃): δ_C 176.9 (C=O); 151.4 (C^{7a}_{benzimid.}); 147.9 (C²_{benzimid.}); 130.9 (C^{3a}_{benzimid.} + C⁴_{benzimid.}); 121.6 (C⁵_{benzimid.}); 59.8 (C²_{pyrrol.}); 47.6 (C⁵_{pyrro}); 41.8 (HSCH₂CH); 38.0 (C³_{pyrrol.}); 24.4; (HSCH₂CH); 21.2 (C⁴_{pyrrol.}); 17.0 (CH₃). Anal. Calc. for C₁₄H₁₈N₄OS (290.38): C, 57.91; H, 6.25; N, 19.29%. Found: C, 57.69; H, 6.18; N, 19.03%. MS: m/z (FAB) 291 [M+H]⁺.

1-(2-(9H-Purin-8-yl)pyrrolidin-1-yl)-3-mercapto-2-methylpropan-1-one (13). From pyrimidine-4,5-diamine **7** (110 mg). Yield: 160 mg, (55%), oil. ¹H NMR (CDCl₃): δ_H 8.89 (s, 1H, C⁴_{purin}); 8.83 (s, 1H, C⁵_{purin}); 4.68 (dd, 1H, $J_{2,3a} = 3.6$ Hz, $J_{2,3b} = 8.0$ Hz, $J_{3a,3b} = 11.3$ Hz, H-2); 3.60 (m, 2H, CH₂^{pyrrol.-5}); 3.05 (m, 3H, HSCH₂ + H-2'); 2.42 (m, 2H, CH₂^{pyrrol.-3}); 1.99 (m, 2H, CH₂^{pyrrol.-4}); 1.23 (d, 3H, $J = 3.0$ Hz, CH₃). ¹³C NMR (CDCl₃): δ_C 177.1 (C=O); 152.5 (C⁶_{benzimid.} + C^{7a}_{benzimid.}); 147.8 (C²_{benzimid.} + C⁴_{benzimid.}); 132.3 (C^{3a}_{benzimid.}); 59.9 (C²_{pyrrol.}); 47.5 (C⁵_{pyrrol.}); 41.5 (HSCH₂CH); 38.2 (C³_{pyrrol.}); 24.1; (HSCH₂CH); 21.3 (C⁴_{pyrrol.}); 16.9 (CH₃). MS: m/z (FAB) 314 [M+Na]⁺.

1-(2-(Benzothiazol-2-yl)pyrrolidin-1-yl)-3-mercapto-2-methylpropan-1-one (14). From 2-aminobenzenethiol **8** (125 mg). Yield: 156 mg (51%), oil. ¹H NMR (CDCl₃): δ_H 7.86-7.60 (M, 4H, Ar-H); 4.60 (dd, 1H, $J_{2,3a} = 3.7$ Hz, $J_{2,3b} = 8.0$ Hz, $J_{3a,3b} = 11.6$ Hz, H-2); 3.62 (m, 2H, CH₂^{pyrrol.-5}); 3.01 (m, 3H, HSCH₂ + H-2'); 2.11 (m, 2H, CH₂^{pyrrol.-3}); 1.97 (m, 2H, CH₂^{pyrrol.-4}); 1.29 (d, 3H, $J = 3.1$ Hz, CH₃). ¹³C NMR (CDCl₃): δ_C 176.6 (C=O); 165.9 C²_{benzimid.}); 148.2 (C^{3a}_{benzimid.}), 135.5 C^{7a}_{benzimid.}); 130.9, 124.8, 121.2 (C⁵_{benzimid.} - C⁸_{benzimid.}); 62.4 (C²_{pyrrol.}); 47.6 (C⁵_{pyrrol.}); 41.8 (HSCH₂CH); 38.4 (C³_{pyrrol.}); 24.8; (HSCH₂CH); 21.2 (C⁴_{pyrrol.}); 17.5 (CH₃). MS: m/z (FAB) 329 [M+Na]⁺.

1-(3-(Carboxymethylthio)-2-methylpropanoyl)pyrrolidine-2-carboxylic acid (15). To a solution of **2** (326 mg, 1.5 mmol) in DMF (20 ml) containing Et₃N (152 mg, 1.5 mmol) was added 2-chloroacetic acid (142 mg, 1.50 mmol) and stirred at 23 °C for 16 h. The mixture was evaporated to dryness and the residue was partitioned between CHCl₃ (2x20 ml) and water (30 ml) and the organic extract was dried (Na₂SO₄), filtered and evaporated to dryness. The residue was purified on a SiO₂ column (10 g) and eluted with CHCl₃-MeOH (4:1) to give **15** (281 mg, 68%), semi-solid. ¹H NMR (DMOS-*d*₆ + D₂O): δ_H 4.38 (dd, 1H, $J_{2,3a} = 3.3$ Hz, $J_{2,3b} = 6.4$ Hz, $J_{3a,3b} = 11.4$ Hz, H²_{pyrrol.}); 3.66 (s, 2H, SCH₂CO₂D); 3.58 (m, 2H, CH₂^{pyrrol.-5}); 2.91 (m, 3H, H-2' + SCH₂-H-2'); 2.11 (m, 2H, CH₂^{pyrrol.-3}); 1.97 (m, 2H, CH₂^{pyrrol.-4}); 1.28 (d, 3H, $J = 3.1$ Hz, CH₃). ¹³C NMR (DMOS-*d*₆): δ_C 176.9, 173.4 (C=O); 59.0 (C²_{pyrrol.}); 47.0 (C⁵_{pyrrol.}); 42.1 (DCO₂CH₂S); 40.8 (CHCH₂S); 37.3 (CHCH₂S); 28.4 (C³_{pyrrol.}); 24.4 (C⁴_{pyrrol.}); 16.5 (CH₃). Anal. Calc. for C₁₁H₁₇NO₅S (275.32): C, 47.99; H, 6.22; N, 5.09%. Found: C; 47.74; H; 6.14 N, 4.87%. MS: m/z (FAB) 298 [M+Na]⁺.

1-(3-(2-Amino-2-oxoethylthio)-2-methylpropanoyl)pyrrolidine-2-carboxylic acid (16). This compound was prepared following the procedure of preparation of **15**, from **2** (326 mg, 1.5 mmol) in DMF (20 ml) containing Et₃N (152 mg, 1.5 mmol) and 2-chloroacetamide (139 mg, 1.5 mmol) to give after chromatography **17** (296 mg, 72%); mp 208-210 °C (dec.). ¹H NMR

(DMOS- d_6 + D $_2$ O): δ_H 4.35 (dd, 1H, $J_{2,3a} = 3.2$ Hz, $J_{2,3b} = 6.2$ Hz, $J_{3a,3b} = 11.5$ Hz, H $^2_{pyrrol.}$); 3.59 (s, 2H, SCH $_2$ COND $_2$); 3.50 (m, 2H, CH $_2^{pyrrol.-5}$); 2.80 (m, 3H, H-2' + SCH $_2$ -H-2'); 2.22 (m, 2H, CH $_2^{pyrrol.-3}$); 1.99 (m, 2H, CH $_2^{pyrrol.-4}$); 1.22 (d, 3H, $J = 3.1$ Hz, CH $_3$). ^{13}C NMR (DMOS- d_6 + D $_2$ O): δ_C 177.9 (C=O); 173.9 (CO $_2$ D); 169.4 (CO $_2$ ND $_2$); 60.4 (C $^2_{pyrrol.}$); 46.5 (C $^5_{pyrrol.}$); 43.7 (D $_2$ NCOCH $_2$ S); 38.4 (MeCHCH $_2$ S); 34.3 (MeCHCH $_2$ S); 28.0 (C $^3_{pyrrol.}$); 23.0 (C $^4_{pyrrol.}$); 16.5 (CH $_3$). Anal. Calc. for C $_{11}$ H $_{18}$ N $_2$ O $_4$ S (274.34): C, 48.16; H, 6.61; N, 10.21%. Found: C, 47.97 H, 6.59; N, 10.02%. MS: m/z (FAB) 297 [M+Na] $^+$.

1-(3-(2-(Phthalimido-2-yl)-2-ethylthio)-2-methylpropanyl)pyrrolidine 2-carboxylic acid (17). A mixture of **2** (217 mg, 1.0 mmol) in EtOH (20 ml), 2-chloroethyl-phthalimide (231 mg, 1.1 mmol) containing Et $_3$ N (111 mg, 1.1 mmol) was heated under reflux for 5 h. After cooling, the mixture was worked up as in **15** to give after chromatography, using SiO $_2$ (10 g) and toluene-EtOAc (7:3) as eluent, **17** (304 mg, 78%), mp 147-151 °C (from acetone-ether). 1H NMR (CDCl $_3$): δ_H 7.89-7.60 (m, 4H, Ar-H); 4.35 (dd, 1H, $J_{2,3a} = 3.4$ Hz, $J_{2,3b} = 6.9$ Hz, $J_{3a,3b} = 11.6$ Hz, H $^2_{pyrrol.}$); 3.96 (m, 2H, SCH $_2$ CH $_2$ -phthalimide); 3.55 (m, 2H, CH $_2^{pyrrol.-5}$); 2.85-2.79 (m, 5H, H-2' + SCH $_2$ CHMe + SCH $_2$ CH $_2$ -phthalimide); 2.18 (m, 2H, CH $_2^{pyrrol.-3}$); 2.01 (m, 2H, CH $_2^{pyrrol.-4}$); 1.25 (d, 3H, $J = 3.3$ Hz, CH $_3$). ^{13}C NMR (CDCl $_3$): δ_C 176.8 (C=O); 173.9 (CO $_2$ H); 166.8 (C $_{phthalimid=O}$); 131.8, 130.6, 126.9 (C $_{phthalimid}$); 60.2 (C $^2_{pyrrol.}$); 46.4 (C $^5_{pyrrol.}$); 40.1 (SCH $_2$ CHMe); 33.7 (SCH $_2$ CH $_2$ -phthalimide + SCH $_2$ CHMe); 28.6 (SCH $_2$ CH $_2$ -phthalimide + C $^3_{pyrrol.}$); 24.0 (C $^4_{pyrrol.}$); 16.5 (CH $_3$). Anal. Calc. for C $_{19}$ H $_{22}$ N $_2$ O $_5$ S (390.45): C, 58.45; H, 5.68; N, 7.17. Found: C, 58.19; H, 5.52; N, 6.89. MS: m/z (FAB) 391 [M+H] $^+$.

1-(3-(2-(4-(1-Benzyl-2-ethyl-4-nitro-imidazol-5-yl)-piperazin-1-yl)-2-oxoethylthio)-2-methylpropanoyl)pyrrolidine-2-carboxylic acid (19). A solution of **2** (217 mg, 1.0 mmol) in EtOH (20 ml) containing NaOAc (90 mg, 1.1 mmol) was treated with **18** (430 mg, 1.1 mmol) and the mixture was stirred at 23 °C for 16 h. The mixture was filtered and the solvent was evaporated to dryness and the residue was recrystallized from EtOH to give **19** (383 mg, 67%), mp 157-161 °C (dec.). 1H NMR (DMSO- d_6): δ_H 7.33 (m, 3H, ArH); 7.00 (m, 2H, Ar); 5.13 (s, 2H, CH $_2$ Ph); 4.31 (dd, 1H, $J_{2,3a} = 3.5$ Hz, $J_{2,3b} = 7.0$ Hz, $J_{3a,3b} = 11.6$ Hz, H $^2_{pyrrol.}$); 3.61 (s, 2H, SCH $_2$ CO); 3.53 (m, 2H, CH $_2^{pyrrol.-5}$); 3.44 (br s., 8H, H $_{piperazin}$); 2.90 (m, 3H, H-2' + SCH $_2$ -H-2'); 2.60 (q, 2H, $J = 7.5$ Hz, CH $_2$ CH $_3$); 2.16 (m, 2H, CH $_2^{pyrrol.-3}$); 2.03 (m, 2H, CH $_2^{pyrrol.-4}$); 1.30 (t, 3H, CH $_2$ CH $_3$); 1.24 (d, 3H, $J = 3.2$ Hz, CH $_3$). ^{13}C NMR (DMSO- d_6): δ_C 176.6 (C=O); 173.6 (CO $_2$ H); 167.1 (C=O); 155.2 (C $^2_{imidazol}$); 145.0 (C $^4_{imidazol}$); 139.7 (C $^5_{imidazol}$); 138.1, 135.2, 129.1, 128.1, 125.7 (Ar); 60.2 (C $^2_{pyrrol.}$); 49.1, 46.2 (4C, piperazine); 46.4 (C $^5_{pyrro}$); 42.1 (CH $_2$ Ph); 40.0 (SCH $_2$ CHMe + SCH $_2$ CO); 33.9 (SCH $_2$ CHMe); 28.4 (C $^3_{pyrrol.}$); 24.1 (C $^4_{pyrrol.}$); 21.1 (CH $_2$ CH $_3$); 16.4. (CH $_3$); 11.2 (CH $_2$ CH $_3$). Anal. Calc. for C $_{27}$ H $_{36}$ N $_6$ O $_6$ S (572.68): C, 56.63; H, 6.34; N, 14.67%. Found: C, 56.41; H, 6.29; N, 14.23%. MS: m/z (FAB) 548 [M+H] $^+$.

***N*-(2-(4-(Benzothiazol-2-yl)piperazin-1-yl)-2-oxoethyl)-1-(3-mercapto-2-methylpropanoyl)pyrrolidine-2-carboxamide (21).** To a cold solution of **2** (217 mg, 1.0 mmol), at -5 °C, in MeCN (10 ml), 3-amino-1-(4-(benzothiazol-2-yl)piperazin-1-yl)ethanone **20** (276 mg, 1.0 mmol), hydroxybenzotriazole (HOBt) (135 mg, 1.0 mmol) and *N,N'*-dicyclohexyl-carbodiimide (DCC) (206 mg, 1.0 mmol) were added successively. The reaction mixture was stirred at 0 °C

for 1 h, at 5 °C for 1 h, and at 23 °C for 16 h. Dicyclohexylurea (DCU) was filtered, and the filtrate was evaporated to dryness and the residue was dissolved in ethyl acetate, filtered, washed successively with saturated NaCl solution, 5% NaHCO₃ solution, 1.0 M HCl, followed by washing with saturated NaCl solution and finally with water. The residue was dried (Na₂SO₄), filtered, evaporated to dryness and the residue was purified on a silica gel column (10 g). Elution, in gradient, with MeOH (0-10%) and CHCl₃ as eluent afforded **21** (333 mg, 70%), semi-solid. ¹H NMR (DMSO-*d*₆): δ_H 8.21-7.49 (m, 4H, ArH); 4.39 (dd, 1H, *J*_{2,3a} = 3.4 Hz, *J*_{2,3b} = 7.2 Hz, *J*_{3a,3b} = 11.5 Hz, H²_{pyrrol.}); 3.97 (s, 2H, CH₂NCO); 3.52 (m, 2H, CH₂^{pyrrol.}-5); 3.42 (br s., 8H, H_{piperazin}); 2.91 (m, 3H, H-2' + HSCH₂); 2.29 (m, 2H, CH₂^{pyrrol.}-3); 2.01 (m, 2H, CH₂^{pyrrol.}-4); 1.23 (d, 3H, *J* = 3.3 Hz, CH₃). ¹³C NMR (DMSO-*d*₆): δ_C 177.9 (C=O); 170.7 (CONCH₂); 167.7 (CO-piperazine); 166.6 (C²_{benzothiazol}); 147.8 (C^{3a}_{benzothiazol}); 125.7, 125.1, 124.7, 121.7 (C_{benzothiazol}); 60.5 (C²_{pyrrol.}); 49.3, 46.5 (4C, piperazine); 45.4 (C⁵_{pyrro}); 40.9 (CH₂NCO + CHCH₂SH); 28.7 (C³_{pyrrol.}); 24.2 (CHCH₂SH); 22.0 (C⁴_{pyrrol.}); 16.2 (CH₃). Anal. Calcd for C₂₂H₂₉N₅O₃S₂ (475.63): C, 56.56; H, 6.15; N, 14.72%. Found; C, 56.41; H, 6.29; N, 14.23%. MS: *m/z* (FAB) 476 [M+H]⁺.

Acknowledgements

We thank Mr. U. Haunz and Miss A. Friemel of the Chemistry Department, University of Konstanz, Germany for the NMR experiments.

References

1. Gallant, J. E. *Clin. Virol.* **2002**, *25*, 317.
2. van Rossum, A. M. C.; Fraaij, P. L. A.; de Groot, R. *Lancet. Infect. Dis.* **2002**, *2*, 93.
3. Joly, V.; Yeni, P. *Eur. J. Int. Med.* **2000**, *11*, 301-308.
4. Jonckheere, H.; Anné, J.; De Clercq, E. *Med. Res. Rev.* **2000**, *20*, 129.
5. Vella, S.; Palmisano, L. *Antiviral Res.* **2000**, *45*, 1.
6. Sham, H. L.; Kempf, D. J.; Molla, A.; Marsh, K. C.; Kumar, G. N.; Chen, C.-M.; Kati, W.; Stewart, K.; Lal, R.; Hsu, A.; Betebenner, D.; Korneyeva, M.; Vasavanonda, S.; McDonald, E.; Saldivar, A.; Wideburg, N.; Chen, X.; Niu, P.; Park, C.; Jayanti, V.; Grabowski, B.; Granneman, G. R.; Sun, E.; Japour, A. J.; Leonard, J. M.; Plattner, J. J.; Norbeck, D. W. *Antimicrob. Agents Chemother.* **1998**, *42*, 3218.
7. Wlodawer, A. *Curr. Opin. Anti-Infect. Investig. Drugs I* **1999**, 246.
8. Kempf, D. J.; March, K. C.; Denissen, J. F.; McDonald, E.; Vasavanoda, S.; Flentge, C. A.; Green, B. E.; Fino, L.; Park, C. P.; Kong, X.; Wideburg, N. E.; Saldivar, A.; Ruitz, L.; Kati, W. M.; Sham, H. L.; Robins, T.; Stewart, K. D.; Hsu, A.; Plattner, J. J.; Leonard, J. M.; Norbeck, D. W. *Proc. Acad. Sci. USA* **1995**, *92*, 2484.

9. Thakuria H.; Das, G. *Arkivoc* **2008**, (xv), 321-328, and references cited therein.
10. Chimirri, A.; Grasso, S.; Monforte, A. M.; Monforte, P.; Zappalà, M. *Il Farmaco* **1991**, *46*, 817.
11. Chimirri, A.; Grasso, S.; Monforte, A. M.; Monforte, P.; Zappalà, M. *Il Farmaco* **1991**, *46*, 925.
12. Chimirri, A.; Grasso, S.; Molica, C.; Monforte, A. M.; Monforte, P.; Zappalà, M. *Il Farmaco* **1996**, *51*, 279.
13. Chimirri, A.; Grasso, S.; Monforte, P.; Rao, A.; Zappalà, M.; Monforte, A. M.; Pannecouque, C.; Witvrouw, M.; Balzarini, J.; De Clercq, E. *Antiviral Chem. Chemother.* **1999**, *10*, 211.
14. Rao, A.; Chimirri, A.; Ferro, S.; Monforte, A. M.; Monforte, P.; Zappalà, M. *Arkivoc* **2004**, (v), 145.
15. Ali, I. A. I.; Al-Masoudi, I. A.; Saeed, B.; Al-Masoudi, N. A.; La Colla, P. *Heteroatom Chem.* **2005**, *16*, 148.
16. Al-Masoudi, N. A.; Al-Masoudi, I. A.; Ali, I. A. I.; Saeed, B.; La Colla, P. *Heteroatom Chem.* **2005**, *16*, 576.
17. Al-Masoudi, N. A., Al-Soud, Y. A., Pannecouque, C.; De Clercq, E. *Antiviral Chem. Chemother.* **2007**, *18*, 191.
18. Al-Soud, Y. A.; Al-Masoudi, N. A.; Hassan, H. Gh.; De Clercq, E.; Pannecouque, C. *Acta Pharm.* **2007**, *57*, 379.
19. Al-Soud, Y. A.; Al-Sadoni, H. H.; Amajaour, H. A. S.; Salih, K. S. M.; Mubarak, M. S.; Al-Masoudi, N.A.; Jaber, I. H. *Z. Naturforsch.* **2008**, *63b*, 83.
20. Akhtar, T.; Hameed, S.; Al-Masoudi, N. A. *Acta Pharma.* **2008**, *58*, 135.
21. Al-Masoudi, I. A.; Al-Soud, Y. A.; Hussien, S.; Schuppler, T.; Al-Masoudi, N. A. *Phosphorus, Sulfur, Silicon* **2008**, *183*, 1571.
22. Al-Masoudi, N. A.; Al-Soud, Y. A. *Nucleosides Nucleotides Nucleic Acids* **2008**, *27*, 1034.
23. Al-Masoudi, N. A.; Aziz, N. M.; Mohammed, A. T. *Phosphorus, Sulfur, Silicon* **2009**, *184*, 2891.
24. (a) Ondetti, M. A.; Rubin, B.; Cushman, D. W. *Science* **1977**, *196*, 441-444. (b) Cushman, D. W.; Cheung, H. S.; Sabo, E. F.; Ondetti, M. A. *Biochemistry* **1977**, *16*, 5484.
25. Willker, W.; Leibfritz, D.; Kerssebaum, R.; Bermel, W. *Mag. Reson. Chem.* **1993**, *31*, 287.
26. Roark, W.H.; Tinney, F. J.; Cohen, D.; Essenburg, A. D.; Kaplan, H. R. *J. Med. Chem.* **1985**, *28*, 1291.
27. Asagarasu, A.; Uchiyama, T.; Achiwa, K. *Chem. Pharm. Bull.* **1986**, *46*, 697.
28. Davis, S.; Mohammed, A. K. *J. Chem. Soc. Perkin Trans. 1* **1981**, 2982.
29. König, W.; Geiger, R. *Chem. Ber.* **1970**, *103*, 788.
30. Pennigton, R. M.; Fischer, R. R. *J. Biol. Chem.* **1981**, *256*, 8963.
31. Katritzky, A. R.; Suzuki, K.; Singh, S. K. *Arkivoc* **2004**, (i), 12.
32. Al-Soud, Y. A.; Al-Sa'doni, H. H.; Saeed, B.; Jaber, I. H.; Beni-Khalid, M. O.; Al-Masoudi, N. A.; Abdul-Kadir, T.; La Colla, P.; Busonera, B.; Sanna, T.; Loddo, R. *Arkivoc* **2008**, (xv), 225.

33. Pauwels, R.; Balzarini J.; Baba, M.; Snoeck, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; De Clercq, E. *J. Virol. Methods* **1988**, *20*, 309.
34. Hargrave, K. D.; Proudfoot, J. R.; Grozinger, K. G.; Cullen, E.; Kapadia, S. R.; Patel, U. R.; Fuchs, V. U.; Mauldin, S. C.; Vitous, J.; Behnke, M. L.; Klunder, J. M.; Pal, K.; Skiles, J. W.; McNeil, D. W.; Rose, J. M.; Chow, G. C.; Skoog, M. T.; Wu, J. C.; Schmidt, G.; Engel, W. W.; Eberlein, W. G.; Saboe, T. D; Campbell, S. J.; Rosenthal, A. S. J. Adam, *J. Med Chem.* **1991**, *34*, 2231.
35. Mitsuya, H.; Weinhold, K. J.; Furman, P. A.; St. Clair, M. H.; Lehrmann, S. N.; Gallo, R. C.; Bolognesi, D.; Barry, D. W.; Broder, S. *Proc. Natl. Acad. Sci. USA* **1985**, *82*, 7096.